Humanigen Inc Watch

from 10-K/A 20 pages This Employment Agreement (“Agreement”), Is Dated as of August 24, 2020 (The “Effective Date”), by and Between Humanigen, Inc., a Delaware Corporation With Offices at 533 Airport Blvd, Suite 400, Burlingame, Ca 94010 (The “Corporation”), and Edward P. Jordan, an Individual (“Executive”). the Parties to This Agreement Are the Corporation and Executive, Referred to Individually as the “Party.”

from 10-K 11 pages Certain Identified Information, Marked by [***], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Settlement Agreement

from 10-K 1 page Humanigen, Inc. Compensation for Non-Employee Directors

from 8-K 18 pages This Employment Agreement (“Agreement”), Is Dated as of April 21, 2021 (The “Effective Date”), by and Between Humanigen, Inc., a Delaware Corporation With Offices at 533 Airport Blvd, Suite 400, Burlingame, Ca 94010 (The “Corporation”), and Adrian M Kilcoyne, an Individual (“Executive”). the Parties to This Agreement Are the Corporation and Executive, Each Referred to Individually as the “Party.”

from 10-K 1 page Humanigen, Inc. Compensation for Non-Employee Directors

from 10-Q 11 pages Humanigen, Inc. 2020 Omnibus Incentive Compensation Plan Notice of Stock Option Grant

from 10-Q 12 pages Humanigen, Inc. 2020 Omnibus Incentive Compensation Plan Notice of Stock Option Grant

from 10-Q 49 pages Agreement

from 10-K 6 pages Master Consulting Agreement

from 10-K 12 pages A Cooperative Research and Development Agreement Between Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (Jpeo-Cbrnd) (Laboratory) Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response (Barda) (Laboratory) and Humanigen

from 10-K 40 pages Certain Identified Information, Marked by [***], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Lenzilumab License Agreement Among Humanigen, Inc. Kpm Tech Co., Ltd. and Telcon Rf Pharmaceutical, Inc. Dated: 3 November 2020

from 10-K 20 pages Employment Agreement (“Agreement”), as of July 6, 2020, by and Between Humanigen, Inc., a Delaware Corporation With Offices at 533 Airport Blvd, Suite 400, Burlingame, Ca 94010 (The “Corporation”), and Dr. Dale Chappell, an Individual (“Executive”)

from 10-K 20 pages Employment Agreement (“Agreement”), as of July 6, 2020, by and Between Humanigen, Inc., a Delaware Corporation With Offices at 533 Airport Blvd, Suite 400, Burlingame, Ca 94010 (The “Corporation”), and David L. Tousley, an Individual (“Executive”)

from 10-K 20 pages This Employment Agreement (“Agreement”), Is Dated as of August 1, 2020 (The “Effective Date”), by and Between Humanigen, Inc., a Delaware Corporation With Offices at 533 Airport Blvd, Suite 400, Burlingame, Ca 94010 (The “Corporation”), and Timothy E. Morris, an Individual (“Executive”). the Parties to This Agreement Are the Corporation and Executive, Referred to Individually as the “Party.”

from 10-K 19 pages This Amended and Restated Employment Agreement (“Agreement”), Is Dated as of October 29, 2020 (The “Effective Date”), by and Between Humanigen, Inc., a Delaware Corporation With Its Principal Office at 533 Airport Blvd, Suite 400, Burlingame, Ca 94010 (The “Corporation”), and Dr. Cameron Durrant, an Individual (“Executive”). the Parties to This Agreement Are the Corporation and Executive, Referred to Individually as the “Party.” This Agreement Amends and Restates That Certain Employment Agreement Dated as of July 1, 2016, by and Between the Executive and the Corporation (The “Prior Agreement”), So That Upon the Effectiveness of This Agreement, the Prior Agreement Shall Be of No Further Force and Effect, and Shall Be Superseded and Replaced in Its Entirety by This Agreement

from 10-K 10 pages Indemnity Agreement

from 8-K 23 pages Certain Identified Information, Marked by [***], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Master Service Agreement

from 8-K 14 pages Humanigen, Inc. 2020 Omnibus Incentive Compensation Plan Notice of Stock Option Grant

from 8-K 15 pages Humanigen, Inc. 2020 Omnibus Incentive Compensation Plan Notice of Stock Option Grant

from 8-K 22 pages Humanigen, Inc. 2020 Omnibus Incentive Compensation Plan Contents